Analysts expect PerkinElmer, Inc. (NYSE:PKI) to post $0.94 earnings per share for the current fiscal quarter, according to Zacks. Six analysts have issued estimates for PerkinElmer’s earnings, with the highest EPS estimate coming in at $0.95 and the lowest estimate coming in at $0.92. PerkinElmer posted earnings of $0.83 per share during the same quarter last year, which suggests a positive year over year growth rate of 13.3%. The business is scheduled to issue its next quarterly earnings results after the market closes on Thursday, January 25th.
On average, analysts expect that PerkinElmer will report full year earnings of $2.89 per share for the current year, with EPS estimates ranging from $2.88 to $2.92. For the next fiscal year, analysts expect that the business will post earnings of $3.49 per share, with EPS estimates ranging from $3.43 to $3.56. Zacks’ earnings per share averages are a mean average based on a survey of sell-side research analysts that cover PerkinElmer.
PerkinElmer (NYSE:PKI) last issued its quarterly earnings results on Thursday, November 2nd. The medical research company reported $0.73 earnings per share for the quarter, topping the consensus estimate of $0.72 by $0.01. PerkinElmer had a return on equity of 13.11% and a net margin of 18.27%.
Several equities research analysts have weighed in on PKI shares. Citigroup reissued a “buy” rating and issued a $80.00 price target (up previously from $74.00) on shares of PerkinElmer in a report on Tuesday, September 26th. Goldman Sachs Group reissued a “neutral” rating and issued a $67.00 price target on shares of PerkinElmer in a report on Tuesday, September 26th. Morgan Stanley reissued an “overweight” rating and issued a $77.00 price target (down previously from $79.00) on shares of PerkinElmer in a report on Friday, October 6th. Robert W. Baird reissued a “buy” rating and issued a $72.00 price target on shares of PerkinElmer in a report on Friday, October 20th. Finally, Jefferies Group reissued a “hold” rating and issued a $70.00 price target on shares of PerkinElmer in a report on Friday, October 20th. One investment analyst has rated the stock with a sell rating, ten have assigned a hold rating and six have assigned a buy rating to the company. The company currently has a consensus rating of “Hold” and an average target price of $73.62.
In related news, insider Andrew Okun sold 12,680 shares of PerkinElmer stock in a transaction dated Friday, December 15th. The stock was sold at an average price of $72.00, for a total transaction of $912,960.00. Following the completion of the sale, the insider now owns 25,121 shares of the company’s stock, valued at $1,808,712. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Frank Anders Wilson sold 37,535 shares of the business’s stock in a transaction that occurred on Thursday, December 7th. The shares were sold at an average price of $70.14, for a total value of $2,632,704.90. The disclosure for this sale can be found here. Insiders have sold 86,336 shares of company stock valued at $6,114,917 in the last ninety days. Corporate insiders own 2.20% of the company’s stock.
A number of large investors have recently made changes to their positions in the business. State of Alaska Department of Revenue lifted its holdings in PerkinElmer by 111.8% in the fourth quarter. State of Alaska Department of Revenue now owns 18,850 shares of the medical research company’s stock valued at $1,376,000 after acquiring an additional 9,950 shares during the period. Oakbrook Investments LLC acquired a new position in PerkinElmer in the fourth quarter valued at approximately $301,000. Schwab Charles Investment Management Inc. lifted its holdings in PerkinElmer by 3.3% in the fourth quarter. Schwab Charles Investment Management Inc. now owns 648,194 shares of the medical research company’s stock valued at $47,396,000 after acquiring an additional 20,823 shares during the period. Cutler Group LP lifted its holdings in PerkinElmer by 845.7% in the fourth quarter. Cutler Group LP now owns 2,237 shares of the medical research company’s stock valued at $163,000 after acquiring an additional 2,537 shares during the period. Finally, Bank of Montreal Can lifted its holdings in PerkinElmer by 31.0% in the fourth quarter. Bank of Montreal Can now owns 52,240 shares of the medical research company’s stock valued at $3,820,000 after acquiring an additional 12,372 shares during the period. 91.37% of the stock is owned by institutional investors.
Shares of PerkinElmer (NYSE PKI) traded up $1.32 during midday trading on Friday, reaching $80.86. The company’s stock had a trading volume of 499,393 shares, compared to its average volume of 427,464. The company has a debt-to-equity ratio of 0.44, a quick ratio of 2.09 and a current ratio of 2.59. The firm has a market capitalization of $8,912.79, a P/E ratio of 22.46, a PEG ratio of 1.91 and a beta of 0.77. PerkinElmer has a fifty-two week low of $50.59 and a fifty-two week high of $80.90.
The company also recently announced a quarterly dividend, which will be paid on Friday, February 9th. Investors of record on Friday, January 19th will be issued a dividend of $0.07 per share. This represents a $0.28 dividend on an annualized basis and a dividend yield of 0.35%. The ex-dividend date is Thursday, January 18th. PerkinElmer’s dividend payout ratio (DPR) is 7.78%.
COPYRIGHT VIOLATION NOTICE: “PerkinElmer, Inc. (PKI) Expected to Announce Earnings of $0.94 Per Share” was published by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this piece of content on another publication, it was stolen and reposted in violation of United States and international trademark & copyright laws. The correct version of this piece of content can be read at https://www.dispatchtribunal.com/2018/02/13/perkinelmer-inc-pki-expected-to-announce-earnings-of-0-94-per-share.html.
PerkinElmer, Inc is a provider of products, services and solutions to the diagnostics, research, environmental, industrial and laboratory services markets. The Company operates through two segments: Discovery & Analytical Solutions and Diagnostics. The Discovery & Analytical Solutions segment serves the environmental, food, industrial, life sciences research and laboratory services markets.
Get a free copy of the Zacks research report on PerkinElmer (PKI)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for PerkinElmer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PerkinElmer and related companies with MarketBeat.com's FREE daily email newsletter.